BIX 01294

Pricing Availability   Qty
说明: GLP and G9a inhibitor
化学名: 2-(Hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-6,7-dimethoxy-N-[1-(phenylmethyl)-4-piperidinyl]-4-quinazolinamine trihydrochloride
纯度: ≥98% (HPLC)
说明书
引用文献 (4)
评论
实验方案 (1)
文献 (2)

生物活性 for BIX 01294

BIX 01294 is a GLP and G9a histone lysine methyltransferase inhibitor (IC50 values are 0.7 and 1.7 μM respectively) that displays no activity at other histone methyltransferases up to 37 μM. Modulates H3K9me2 levels in mammalian cells and potentiates induction of pluripotent stem cells from somatic cells in vitro. Also inhibits H3K36 methylation by oncoproteins NSD1, NSD2 and NSD3 (IC50 values are 40 - 112 μM). Restores metabolic and antiviral function in exhausted CD8+ T cells from patients with chronic HCV infection.

For more information about how BIX 01294 trihydrochloride may be used, see our protocol: Converting Fibroblasts into Cardiomyocytes (9C Cocktail)

External Portal Information for BIX 01294

Chemicalprobes.org is a portal that offers independent guidance on the selection and/or application of small molecules for research. The use of BIX-01294 is reviewed on the chemical probes website.

化合物库 for BIX 01294

BIX 01294 is also offered as part of the Tocriscreen 2.0 Max, Tocriscreen Epigenetics Library and Tocriscreen Stem Cell Library. 了解 Tocris 化合物库的更多信息。

技术数据 for BIX 01294

分子量 600.02
公式 C28H38N6O2.3HCl
储存 Desiccate at RT
纯度 ≥98% (HPLC)
CAS Number 1392399-03-9
PubChem ID 46945860
InChI Key FMURUEPQXKJIPS-UHFFFAOYSA-N
Smiles CN(CCC3)CCN3C2=NC1=CC(OC)=C(OC)C=C1C(NC4CCN(CC5=CC=CC=C5)CC4)=N2.Cl.Cl.Cl

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

溶解性数据 for BIX 01294

溶剂 最高浓度 mg/mL 最高浓度 mM
溶解性
water 60 100
DMSO 60 100

制备储备液 for BIX 01294

以下数据基于产品分子量 600.02。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

选择批次从而根据批次分子量重新计算:
浓度/溶剂体积/质量 1 mg 5 mg 10 mg
1 mM 1.67 mL 8.33 mL 16.67 mL
5 mM 0.33 mL 1.67 mL 3.33 mL
10 mM 0.17 mL 0.83 mL 1.67 mL
50 mM 0.03 mL 0.17 mL 0.33 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

产品说明书 for BIX 01294

分析证书/产品说明书
选择另一批次:

参考文献 for BIX 01294

参考文献是支持产品生物活性的出版物。

Kubicek et al (2007) Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol.Cell 25 473 PMID: 17289593

Chang et al (2009) Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294. Nat.Struct.Mol.Biol. 16 312 PMID: 19219047

Shi et al (2008) Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds. Cell Stem Cell 3 568 PMID: 18983970

Malmquist et al (2012) Small-molecule histone methyltransferase inhibitors display rapid antimalarial activity against all blood stage forms in Plasmodium falciparum. Proc.Natl.Acad.Sci.U.S.A. 109 16708 PMID: 23011794

Morishita et al (2017) BIX-01294 inhibits oncoproteins NSD1, NSD2, and NSD3. Med.Chem.Res. 26 2038

Barili et al (2020) Targeting p53 and histone methyltransferases restores exhausted CD8+ T cells in HCV infection. Nat.Commun. 11 604 PMID: 32001678


If you know of a relevant reference for BIX 01294, please let us know.

按产品操作查看相关产品

查看全部 G9a/GLP Inhibitors

关键词: BIX 01294, BIX 01294 supplier, G9a-like, protein, and, G9a, histone, lysine, methyltransferases, HMTases, inhibitors, inhibits, BIX01294, stem, cells, epigenetics, oncoproteins, NSD1, NSD2, NSD3, CD8+, T, exhaustion, exhausted, viral, infections, Stem, Cell, Reprogramming, Lysine, Methyltransferases, G9a/GLP, 3364, Tocris Bioscience

4 篇 BIX 01294 的引用文献

引用文献是使用了 Tocris 产品的出版物。 BIX 01294 的部分引用包括:

Li et al (2018) Epigenetic control of IL-23 expression in keratinocytes is important for chronic skin inflammation. Nat Commun 9 1420 PMID: 29650963

Plews et al (2011) Activation of pluripotency genes in human fibroblast cells by a novel mRNA based approach. Diabetes 5 e14397 PMID: 21209933

Bellamy et al (2020) Increased Efficacy of Histone Methyltransferase G9a Inhibitors Against MYCN-Amplified Neuroblastoma. Front Oncol 10 PMID: 32537432

Li et al (2019) Negative regulation of p53-induced senescence by N-WASP is crucial for DMBA/TPA-induced skin tumor formation. Cancer Res PMID: 30894371


您是否知道使用了 Tocris BIX 01294 的优秀论文? 请告知我们.

BIX 01294 的评论

目前没有该产品的评论。 Be the first to review BIX 01294 and earn rewards!

Have you used BIX 01294?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

BIX 01294 实验方案

以下实验方案包含使用 BIX 01294(目录编号 3364)的更多信息。

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


Epigenetics Scientific Review

Epigenetics Scientific Review

Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.

Epigenetics in Cancer Poster

Epigenetics in Cancer Poster

This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.